In the Claims:

1. (original) A compound of formula



IA

or of formula



IB

wherein

W is CH or N,

R_1 is hydroxy, (C_{1-6})alkoxy, halo(C_{1-6})alkoxy, hydroxycarbonyl(C_{1-6})alkoxy or (C_{1-6})alkoxycarbonyl(C_{1-6})alkoxy,

R_2 is hydrogen or an ester moiety,

R_3 is hydrogen, (C_{1-6})alkyl, (C_{2-6})alkenyl or (C_{3-8})cycloalkyl,

R_4 is hydrogen or (C_{1-6})alkyl,



is cyclohexyl or phenyl,

R_5 and R_6 independently of each other are hydrogen; (C_{1-6})alkyl; (C_{2-6})alkenyl; (C_{6-18})arylcarbonyl; (C_{1-6})alkylcarbonyl; (C_{6-18})aryloxy(C_{1-4})alkylcarbonyl; $(C_{1-}$

$_6$)alkylcarbonyl-

(C_{6-18})arylcarbonyl; heterocyclyl(C_{1-6})alkylcarbonyl, wherein heterocyclyl comprises 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O or S;

(C_{1-6})alkylsulfonyl or

(C_{6-18})arylsulfonyl,

X is NH, O, S or N-R_8, wherein R_8 is (C_{1-6})alkyl or (C_{3-8})cycloalkyl,

Y is O or S, and

n and m independently of each other are 0 or 1.

2. (previously presented) The compound of claim 1 wherein

W is CH or N,

R_1 is hydroxy, methoxy, fluoromethoxy or (hydroxycarbonyl)(dimethyl)methoxy,

R_2 is hydrogen,

R_3 is hydrogen; (C_{1-4})alkyl, e.g. methyl or ethyl; allyl or cyclopropyl,

R_4 is hydrogen or (C_{1-4})alkyl, e.g. methyl,



is cyclohexyl, e.g. and the $-(CH_2)_m$-NR_5R_6 group is in the ortho, meta or para position,

R_5 and R_6 independently of each other are hydrogen; (C_{1-3})alkyl; allyl; (C_{1-4})alkylcarbonyl; phenylcarbonyl, wherein phenyl is optionally substituted by (C_{1-4})alkylcarbonyloxy; phenyoxymethylcarbonyl; phenylsulfonyl, wherein phenyl is substituted by amino or(C_{1-4})alkylcarbonylamino, or heterocyclyl comprising 5 ring members and 1 heteroatom selected from N, O or S,

X is NH, NCH_3, $NCH(CH_3)_2$, O, S or (C_{3-8})cycloalkyl substituted by amino,

n is 0, m is 0,

Y is S and

R_8 is C_{1-4})alkyl.

3. (previously presented) The compound of claim 1 wherein in formula IA

W is N or CH,

R_1 is hydroxy or fluoromethoxy,

R_2, R_4, R_5 and R_6 are hydrogen,

R_3 is C_{1-4})alkyl,



is cyclohexyl,

X is NH,

n is 1 and m is 1.

4. (previously presented) The compound of claim 1 wherein in formula IA

W is N,

R_1 is fluoromethoxy,

R_2, R_4, R_5 and R_6 are hydrogen,

R_3 is C_{1-4})alkyl,



is phenyl,

X is NH,

n is 1 and m is 0.

5. (previously presented) The compound of claim 1 wherein in formula IA

W is CH or N,

R_1 is hydroxy or fluoromethoxy,

R_2, R_4, R_5 and R_6 are hydrogen,

R_3 is C_{1-4})alkyl,



is phenyl,

X is NH,

n is 1 and m is 1.

6. (previously presented) A compound of formula



7. (currently amended) A compound ~~of claim 1~~ in the form of a salt, said compound being a compound of formula



or of formula



IB

wherein

W is CH or N,

R_1 is hydroxy, (C_{1-6})alkoxy, halo(C_{1-6})alkoxy, hydroxycarbonyl(C_{1-6})alkoxy or (C_{1-6})alkoxycarbonyl(C_{1-6})alkoxy,

R_2 is hydrogen or an ester moiety,

R_3 is hydrogen, (C_{1-6})alkyl, (C_{2-6})alkenyl or (C_{3-8})cycloalkyl,

R_4 is hydrogen or (C_{1-6})alkyl,



is cyclohexyl or phenyl,

R_5 and R_6 independently of each other are hydrogen; (C_{1-6})alkyl; (C_{2-6})alkenyl; (C_{6-18})arylcarbonyl; (C_{1-6})alkylcarbonyl; (C_{6-18})aryloxy(C_{1-4})alkylcarbonyl; (C_{1-6})alkylcarbonyl-(C_{6-18})arylcarbonyl; heterocyclyl(C_{1-6})alkylcarbonyl, wherein heterocyclyl comprises 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O or S; (C_{1-6})alkylsulfonyl or (C_{6-18})arylsulfonyl,

X is NH, O, S or N-R_8, wherein R_8 is (C_{1-6})alkyl or (C_{3-8})cycloalkyl,

Y is O or S, and

n and m independently of each other are 0 or 1.

8. (currently amended) A pharmaceutical composition comprising a compound according to claim ~~claims~~ 1 in association with at least one pharmaceutical excipient.

9. (Canceled)

10. (previously presented) A method of treatment of bacterial diseases which comprises administering to a subject in need of such treatment an effective amount of a compound according to claim 1.

11. (previously presented) A process for preparing a compound of formula IA



IA

or a compound of formula IB



IB

said process comprising reacting a compound of formula III



III

with a compound of formula IVA



IVA

or a compound of formula IVB



IVB

wherein

W is CH or N,

R_1 is hydroxy, (C_{1-6})alkoxy, halo(C_{1-6})alkoxy, hydroxycarbonyl(C_{1-6})alkoxy or (C_{1-6})alkoxycarbonyl(C_{1-6})alkoxy,

R_2 is hydrogen or an ester moiety,

R_3 is hydrogen, (C_{1-6})alkyl, (C_{2-6})alkenyl or (C_{3-8})cycloalkyl,

R_4 is hydrogen or (C_{1-6})alkyl,



is cyclohexyl or phenyl,

R_5 and R_6 independently of each other are hydrogen; (C_{1-6})alkyl; (C_{2-6})alkenyl; (C_{6-18})arylcarbonyl; (C_{1-6})alkylcarbonyl; (C_{6-18})aryloxy(C_{1-4})alkylcarbonyl; (C_{1-6})alkylcarbonyl-(C_{6-18})arylcarbonyl; heterocyclyl(C_{1-6})alkylcarbonyl, wherein heterocyclyl comprises 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O or S; (C_{1-6})alkylsulfonyl or (C_{6-18})arylsulfonyl,

X is NH, O, S or N-R_8, wherein R_8 is (C_{1-6})alkyl or (C_{3-8})cycloalkyl,

Y is O or S, and n and m independently of each other are 0 or 1.